HCA Healthcare, Inc. (HCA)
NYSE: HCA · Real-Time Price · USD
426.16
+6.56 (1.56%)
At close: Oct 17, 2025, 4:00 PM EDT
426.70
+0.54 (0.13%)
Pre-market: Oct 20, 2025, 8:48 AM EDT
HCA Healthcare Stock Forecast
Stock Price Forecast
The 16 analysts that cover HCA Healthcare stock have a consensus rating of "Buy" and an average price target of $425, which forecasts a -0.27% decrease in the stock price over the next year. The lowest target is $370 and the highest is $495.
Price Target: $425 (-0.27%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for HCA Healthcare stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 2 | 2 | 2 | 4 |
| Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Hold | 7 | 6 | 8 | 8 | 9 | 9 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 16 | 16 | 16 | 17 | 19 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Mizuho | Mizuho | Buy Maintains $425 → $475 | Buy | Maintains | $425 → $475 | +11.46% | Oct 17, 2025 |
| UBS | UBS | Strong Buy Maintains $438 → $495 | Strong Buy | Maintains | $438 → $495 | +16.15% | Oct 14, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $470 | Strong Buy | Initiates | $470 | +10.29% | Oct 14, 2025 |
| Keybanc | Keybanc | Buy Maintains $370 → $465 | Buy | Maintains | $370 → $465 | +9.11% | Oct 8, 2025 |
| Wells Fargo | Wells Fargo | Hold Maintains $375 → $412 | Hold | Maintains | $375 → $412 | -3.32% | Oct 7, 2025 |
Financial Forecast
Revenue This Year
75.78B
from 70.60B
Increased by 7.33%
Revenue Next Year
79.09B
from 75.78B
Increased by 4.37%
EPS This Year
26.61
from 22.00
Increased by 20.96%
EPS Next Year
28.68
from 26.61
Increased by 7.79%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.6B | 84.6B | |||
| Avg | 75.8B | 79.1B | |||
| Low | 73.0B | 74.3B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 12.7% | 11.7% | |||
| Avg | 7.3% | 4.4% | |||
| Low | 3.4% | -2.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.26 | 31.02 | |||
| Avg | 26.61 | 28.68 | |||
| Low | 25.12 | 25.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 28.4% | 16.6% | |||
| Avg | 21.0% | 7.8% | |||
| Low | 14.2% | -2.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.